Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Antibiotic resistance, molecular characterizations, and clinical manifestations of Campylobacteriosis at a military medical center in Hawaii from 2012-2016: a retrospective analysis.

Ewers EC, Anisowicz SK, Ferguson TM, Seronello SE, Barnhill JC, Lustik MB, Agee W 3rd, Washington MA, Nahid MA, Burnett MW, Bodhidatta L, Srijan A, Rukasiri S, Wassanarungroj P, Ruekit S, Nobthai P, Swierczewski BE, Lurchachaiwong W, Serichantalergs O, Ngauy V.

Sci Rep. 2018 Aug 6;8(1):11736. doi: 10.1038/s41598-018-29461-z.

2.

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.

Akapirat S, Karnasuta C, Vasan S, Rerks-Ngarm S, Pitisuttithum P, Madnote S, Savadsuk H, Rittiroongrad S, Puangkaew J, Phogat S, Tartaglia J, Sinangil F, de Souza MS, Excler JL, Kim JH, Robb ML, Michael NL, Ngauy V, O'Connell RJ, Karasavvas N; RV305 Study Group.

PLoS One. 2018 Apr 27;13(4):e0196397. doi: 10.1371/journal.pone.0196397. eCollection 2018.

3.

Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.

Ake JA, Schuetz A, Pegu P, Wieczorek L, Eller MA, Kibuuka H, Sawe F, Maboko L, Polonis V, Karasavva N, Weiner D, Sekiziyivu A, Kosgei J, Missanga M, Kroidl A, Mann P, Ratto-Kim S, Anne Eller L, Earl P, Moss B, Dorsey-Spitz J, Milazzo M, Laissa Ouedraogo G, Rizvi F, Yan J, Khan AS, Peel S, Sardesai NY, Michael NL, Ngauy V, Marovich M, Robb ML.

J Infect Dis. 2017 Nov 27;216(9):1080-1090. doi: 10.1093/infdis/jix456.

4.

Antibiotic resistance in Campylobacter and other diarrheal pathogens isolated from US military personnel deployed to Thailand in 2002-2004: a case-control study.

Mason CJ, Sornsakrin S, Seidman JC, Srijan A, Serichantalergs O, Thongsen N, Ellis MW, Ngauy V, Swierczewski BE, Bodhidatta L.

Trop Dis Travel Med Vaccines. 2017 Jul 5;3:13. doi: 10.1186/s40794-017-0056-y. eCollection 2017.

5.

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.

Rerks-Ngarm S, Pitisuttithum P, Excler JL, Nitayaphan S, Kaewkungwal J, Premsri N, Kunasol P, Karasavvas N, Schuetz A, Ngauy V, Sinangil F, Dawson P, deCamp AC, Phogat S, Garunathan S, Tartaglia J, DiazGranados C, Ratto-Kim S, Pegu P, Eller M, Karnasuta C, Montefiori DC, Sawant S, Vandergrift N, Wills S, Tomaras GD, Robb ML, Michael NL, Kim JH, Vasan S, O'Connell RJ; RV305 Study Team.

J Infect Dis. 2017 Apr 15;215(8):1255-1263. doi: 10.1093/infdis/jix099.

6.

Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military Populations.

Slike BM, Creegan M, Marovich M, Ngauy V.

PLoS One. 2017 Jan 3;12(1):e0169247. doi: 10.1371/journal.pone.0169247. eCollection 2017.

7.

Immunoproliferative Small Intestinal Disease Associated with Overwhelming Polymicrobial Gastrointestinal Infection with Transformation to Diffuse Large B-cell Lymphoma.

Ewers EC, Sheffler RL, Wang J, Ngauy V.

Am J Trop Med Hyg. 2016 May 4;94(5):1177-81. doi: 10.4269/ajtmh.15-0831. Epub 2016 Feb 22.

8.

Mouth in Foot Disease.

Melton KS, DeRosa DC, Agee WA 3rd, Pires VL, Yim DG, Ngauy V.

Hawaii J Med Public Health. 2015 Sep;74(9 Suppl 2):30-2.

9.

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.

Karasavvas N, Karnasuta C, Savadsuk H, Madnote S, Inthawong D, Chantakulkij S, Rittiroongrad S, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Siriyanon V, Andrews CA, Barnett SW, Tartaglia J, Sinangil F, Francis DP, Robb ML, Michael NL, Ngauy V, de Souza MS, Paris RM, Excler JL, Kim JH, O'Connell RJ; MOPH-TAVEG Collaboration.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1178-86. doi: 10.1089/AID.2015.0034. Epub 2015 Sep 9.

10.

Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation.

Schuetz A, Deleage C, Sereti I, Rerknimitr R, Phanuphak N, Phuang-Ngern Y, Estes JD, Sandler NG, Sukhumvittaya S, Marovich M, Jongrakthaitae S, Akapirat S, Fletscher JL, Kroon E, Dewar R, Trichavaroj R, Chomchey N, Douek DC, O Connell RJ, Ngauy V, Robb ML, Phanuphak P, Michael NL, Excler JL, Kim JH, de Souza MS, Ananworanich J; RV254/SEARCH 010 and RV304/SEARCH 013 Study Groups.

PLoS Pathog. 2014 Dec 11;10(12):e1004543. doi: 10.1371/journal.ppat.1004543. eCollection 2014 Dec.

11.

Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling.

Wieczorek L, Brown BK, Delsarto Macedo C, Wesberry-Schmierer M, Ngauy V, Rosa Borges A, Michael NL, Marovich MA, Montefiori DC, Polonis VR.

Virology. 2013 Dec;447(1-2):240-8. doi: 10.1016/j.virol.2013.09.014. Epub 2013 Oct 5.

12.

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.

Zolla-Pazner S, deCamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris DE, Tomaras G, Rao M, Billings E, Berman P, Shen X, Andrews C, O'Connell RJ, Ngauy V, Nitayaphan S, de Souza M, Korber B, Koup R, Bailer RT, Mascola JR, Pinter A, Montefiori D, Haynes BF, Robb ML, Rerks-Ngarm S, Michael NL, Gilbert PB, Kim JH.

PLoS One. 2013;8(1):e53629. doi: 10.1371/journal.pone.0053629. Epub 2013 Jan 17.

13.

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, Tomaras GD, Currier JR, Jiang M, Magaret C, Andrews C, Gottardo R, Gilbert P, Cardozo TJ, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Paris R, Greene K, Gao H, Gurunathan S, Tartaglia J, Sinangil F, Korber BT, Montefiori DC, Mascola JR, Robb ML, Haynes BF, Ngauy V, Michael NL, Kim JH, de Souza MS; MOPH TAVEG Collaboration.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1444-57. doi: 10.1089/aid.2012.0103. Epub 2012 Oct 4.

14.

HIV epidemic in Asia: optimizing and expanding vaccine development.

Nitayaphan S, Ngauy V, O'Connell R, Excler JL.

Expert Rev Vaccines. 2012 Jul;11(7):805-19. doi: 10.1586/erv.12.49. Review.

PMID:
22913258
15.

Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.

Rerks-Ngarm S, Paris RM, Chunsutthiwat S, Premsri N, Namwat C, Bowonwatanuwong C, Li SS, Kaewkungkal J, Trichavaroj R, Churikanont N, de Souza MS, Andrews C, Francis D, Adams E, Flores J, Gurunathan S, Tartaglia J, O'Connell RJ, Eamsila C, Nitayaphan S, Ngauy V, Thongcharoen P, Kunasol P, Michael NL, Robb ML, Gilbert PB, Kim JH.

J Infect Dis. 2013 Apr 15;207(8):1195-205. doi: 10.1093/infdis/jis478. Epub 2012 Jul 26.

PMID:
22837492
16.

The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization.

Brown BK, Wieczorek L, Kijak G, Lombardi K, Currier J, Wesberry M, Kappes JC, Ngauy V, Marovich M, Michael N, Ochsenbauer C, Montefiori DC, Polonis VR.

PLoS One. 2012;7(4):e29454. doi: 10.1371/journal.pone.0029454. Epub 2012 Apr 11.

17.

Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH.

N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.

18.

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA.

PLoS One. 2010 Nov 15;5(11):e13983. doi: 10.1371/journal.pone.0013983.

19.

Increased African-American involvement in vaccine studies.

Ngauy V, Bautista CT, Duffy K, Humphries MJ, Lewis Y, Marovich M.

J Clin Epidemiol. 2009 Jan;62(1):111-3. doi: 10.1016/j.jclinepi.2008.08.009. No abstract available.

PMID:
19095169
20.

Surveillance for febrile respiratory infections during Cobra Gold 2003.

Fuller J, Hanley K, Schultz R, Lewis M, Freed NE, Ellis M, Ngauy V, Stoebner R, Ryan M, Russell K.

Mil Med. 2006 May;171(5):357-9.

PMID:
16761881
21.

Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II.

Ngauy V, Lemeshev Y, Sadkowski L, Crawford G.

J Clin Microbiol. 2005 Feb;43(2):970-2.

Supplemental Content

Support Center